cas 105-53-3|| where to buy Diethyl malonate

Название продукции:Diethyl malonate

IUPAC Name:1,3-diethyl propanedioate

Упаковочная единица	Доступно для заказа	Цена ($)	Количество
CM247545-1000g	1-2 Weeks	ȡȺǶ

Только для использования в НИОКР..

Форма запроса

Химическое название

Номер CAS

Количество*

Необходимые спецификации*
(% пробы, категория материала и т.д.)

Контактное лицо*

Электронная почта*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 105-53-3 regularly via the above email.

Дополнительные примечания

Verification code*

refresh

: Номер CAS:105-53-3; Молекулярная формула:C7H12O4; Точка плавления:-; Smiles-код:O=C(OCC)CC(=O)OCC; Плотность:

: Номер в каталоге:CM247545; Молекулярная масса:160.17; Точка кипения:199°C at 760 mmHg; Номер Mdl:; Хранение:Store at room temperature.

: Aliphatic Chain Compounds; Aliphatic chain compounds include aliphatic compounds and chain compounds containing other elements or groups. Aliphatic hydrocarbons are hydrocarbons with the basic properties of aliphatic compounds. In aliphatic compounds, carbon atoms are arranged in straight chain, branched chain or cyclic, which are respectively called straight chain aliphatic hydrocarbons, branched chain aliphatic hydrocarbons and alicyclic hydrocarbons. Some cyclic hydrocarbons are different in nature from aromatic hydrocarbons, and are very similar to aliphatic hydrocarbons. Such cyclic hydrocarbons are called alicyclic hydrocarbons. In this way, aliphatic hydrocarbons become a general term for all hydrocarbons except aromatic hydrocarbons. Aliphatic hydrocarbons and their derivatives (including halogenated hydrocarbons) and alicyclic hydrocarbons and their derivatives are collectively referred to as aliphatic compounds.

: Ensifentrine; Verona Pharma's Ensifentrine was accepted for NDA Review by FDA for chronic obstructive pulmonary disease (COPD) maintenance treatment. COPD is used to describe chronic lung diseases, encompassing emphysema, and chronic bronchitis. Phase 3 ENHANCE trials demonstrated Ensifentrine's efficacy and safety, showing significant improvements in lung function, symptom endpoints, and reducing the rate and risk of COPD exacerbations. Ensifentrine offers a novel mechanism of action. It is a dual inhibitor of phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4); it is also an activator of the cystic fibrosis transmembrane conductance regulator (CFTR).